zentek corporate presentation

A healthier and safer world through nanotechnology.

Nanotechnology and graphene have the potential to protect against pathogens, detect and treat disease, clean our water, make building materials stronger, make products safer and produce cleaner energy. With almost limitless potential to improve people’s lives, we are uniquely positioned to create significant value through our next-generation solutions.

A healthier and safer world through nanotechnology.

Our Mission

We develop innovative nanotechnologies with our partners that improve people’s lives.

Message from our CEO, Mr. Greg Fenton

At Zentek, we work with our partners to create intellectual property by harnessing the power of nanotechnology to enhance existing products and create solutions that improve people’s lives.

Our Core Values

Operating the Zentek Way

We think different and challenge the status quo​.

Nanotechnology helps solve unsolved problems. In order to accomplish this, we leverage our experience and knowledge working with graphene to understand how we can make existing technologies better and uncover novel ways to address common, but significant problems.​

Collaboration and partnerships are part of our DNA​

Nanotechnology and graphene hold tremendous promise to create significant value for a number of different areas in healthcare and beyond. Due to these expansive possibilities, we seek to partner with thought leaders and innovators in the private sector, government and academia to accomplish as much as possible, as efficiently as possible.​

Motivated to improve health and protect people

Opportunities to make a meaningful difference for people through nanotechnology are nearly limitless. These possibilities and working with others that recognize this potential are what motivates us every day.​

Our environment is fast-paced and constantly changing; speed and adaptability are key

Nanotechnology is a nascent industry that is evolving quickly; we are highly adaptable and committed to continuous learning​.

Strategic Priorities

Bringing our ip-backed innovations to market quickly and effectively​.

There is significant need and demand for our existing proprietary healthcare solutions, and they generate cash flow to support future growth and create shareholder value​.

Optimizing our supply chain to enable our partnership opportunities and reduce costs​

Supply chain optimization ensures competitive, consistent and stable input for our proprietary solutions​. A well-established supply chain, production processes and marketing presence in the nanotechnology-enabled health care space gives us an extremely strong footing ahead of potentially tremendous market growth​.

Building an IP portfolio focused on next-gen technologies and large-scale opportunities​

Nanotech has nearly limitless applications. We prioritize the most attractive and practical opportunities to ensure we allocate resources and establish partnerships to functionalize nanotechnology and develop IP in the right areas​. Our extensive portfolio protects our ability to serve large-scale, high-growth health care markets with proprietary solutions​.

Strategically Build Organizational Platform for Growth & Success​

We prioritize people, structure, strategies and access to the right resources to achieve our goals​.

Dedicated to pushing the boundaries of what’s possible in nanotechnology.

Meet our team

Our Facilities

Discover Zentek’s world-class research and development centre.

Explore our facilities

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United Kingdom
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• ROLLS-ROYCE HOLDINGS PLC
• VODAFONE GROUP PLC
• THE EDINBURGH INVESTMENT TRUST PLC
• CMC MARKETS PLC
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• United States
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Trend-Following Stocks
• Dividend Kings
• Undervalued stocks
• Quality stocks
• Ageing Population
• Warren Buffett
• The Golden Age of Video Games
• Cannibal companies
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Zentek Ltd.

Ca98942x1024, biotechnology & medical research.

• Zentek : Corporate Presentation 2024

Company Overview

NASDAQ: ZTEK

TSX-V: ZEN.V

Forward Looking Statement

This presentation is being provided for information purposes only and does not constitute or form part of, and should not be construed as, an offer or invitation to sell or any solicitation of any offer to purchase or subscribe for any securities of Zentek Ltd. (" Zentek " or the " Company ") in Canada, the United States or any other jurisdiction. Trading in the securities of the Company should be construed as highly speculative. This presentation is not, and in no circumstances is it to be construed as, a prospectus, an offering memorandum, an advertisement, or a public offering of securities. No securities regulatory authority or similar authority has reviewed or in any way passed upon the document or the merits of any securities of the Company and any representation to the contrary is an offence. Except as otherwise stated, information included in this presentation is given as of the date hereof. The delivery of this presentation shall not imply that the information herein is correct as of any date after the date hereof. Each recipient should consult its own investment, legal, tax and other advisers regarding the financial, legal, tax, and other aspects of the Company, including whether it is legally permitted to purchase any securities from the Company under applicable laws. The securities of the Company have not been and may not be registered under the United States Securities Act of 1933 , as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered and sold in the United States or to, or for the account or benefit of, U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to a registration statement declared effective by the United States Securities and Exchange Commission .

All dollar amounts referenced herein, unless otherwise indicated, are expressed in US dollars.

No information contained in this presentation constitutes medical advice, and it is not to be used for treatment purposes, or to replace consultation with a qualified medical professional. No information contained herein is intended to diagnose health problems or to take the place of professional medical care. The information contained herein is neither intended to dictate what constitutes reasonable, appropriate or best care for any given health issue, nor is it intended to be used as a substitute for the independent judgment of a physician for any given health issue. All content, including text, graphics, images and information, contained herein is for general information purposes only.

Opinions and estimates disclosed constitute management's judgment and are subject to change without notice, as are any statements of financial market trends, which are based on current market conditions. Management of Zentek does not warrant the accuracy or completeness of the information contained herein.

The presentation may include, in some cases, estimates, projections, forecasts, plans, budgets and similar materials and information regarding or relating to the future operating and financial performance or prospects of Zentek and other anticipated events or results that are not historical facts (collectively, "Forward-Looking Information"). Forward-Looking Information can often be identified by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate" and other words indicating that the statements are forward-looking.Forward-Looking Information in this presentation includes, without limitation, estimates and statements with respect to Zentek objectives and goals, to the effect that Zentek or management expects a stated condition or result to occur, regulatory approvals, the adequacy of financial resources, business plans and strategy, and other events or conditions that may occur in the future. All Forward-Looking Information is subject to risks, uncertainties, estimates and assumptions, including the risks described in the Company's public filings with securities commissions or similar regulatory authorities in Canada which are available on the System for Electronic Document Analysis and Retrieval ("SEDAR"). Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, there can be no assurance that Forward-Looking Information will be realized. Zentek does not warrant or guarantee the Forward-Looking Information in any way. All of the Forward-Looking Information in this presentation is qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management of the Company believes that the expectations conveyed by Forward-Looking Information herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such Forward-Looking Information. The Company undertakes no obligation to update any Forward-Looking Information, even if new information becomes available as a result of future events or if circumstances or management's estimates or opinions should change or for any other reason, except as required by applicable securities laws. The Forward-Looking Information contained herein is presented for the purposes of assisting readers in understanding the Company's plan, objectives and goals and may not be appropriate for other purposes.

The Forward-Looking Information contained herein was prepared by the management of the Company based on information available at the time the presentation was prepared. Unless otherwise stated, information in this presentation is as of May 6, 2024.

No representation, warranty or guarantee, expressed or implied, is made by Zentek or any of its representatives with respect to the accuracy or completeness of any information provided in this presentation. No person is entitled to rely on the accuracy or completeness of this information. Any third-party information contained herein has not been independently verified. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted bylaw), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any person. Readers should consult with their own professional advisors regarding their particular circumstances and the Company assumes no liability for any consequences to the investor of any investment in the Company's securities. Neither Zentek, nor its directors, officers, employees, shareholders or agents shall be liable for any claims, expenses, damages (including direct, indirect, special or consequential damages), loss of profits, or opportunities arising from the use of or reliance on the information contained in this presentation.

A Healthier & Safer World

Through Nanotechnology.

Nanotechnology, including graphene, has the potential to protect against pathogens, detect and treat disease, clean our water, make building materials stronger, make products safer

One Company; Many Compelling Opportunities

The Growing Indoor Air Quality Market

The indoor air quality (IAQ) market is experiencing robust growth, driven by the increasing post pandemic demand for energy-efficient solutions.

Bioscience & Pharmaceuticals

The bioscience and pharmaceutical market is continuously growing driven by innovations in drug development and a focus on personalized medicine.

EV Revolution & Mineral Asset

The electric vehicle revolution is accelerating, fueled by advancements in battery technology, supportive government policies, and a growing consumer shift towards sustainable transportation options.

Financial Snapshot

Business Model

Intellectual Property

Secure exclusive rights to our innovative ideas, designs, and unique products

Research & Development

Harness nanotechnology to enhance existing products to solve large-scale problems

Partnerships

Work with manufacturing, distribution, industry professionals and government partners

Go To Market

Bring valuable new solutions to existing markets

Graphene Opportunities

Product Technology Readiness Levels

Enhanced HVAC and PPE Filtration

Enhanced Air Filters

Could Be the Future of

Air Filtration.

How it Works

Transmission through airborne aerosols

• Hydrophilic (water attracting)
• Efficient carrier of Ag+ ions
• High specific surface area

Highly Synergistic Compound Aimed at

Increasing Viral Filtration Efficiency

Enhanced Protection

Against viruses

Attachments

• Original Link
• Original Document

Zentek Ltd. published this content on 07 May 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 07 May 2024 12:48:05 UTC .

Latest news about Zentek Ltd.

Chart Zentek Ltd.

Company Profile

Income statement evolution, quarterly revenue - rate of surprise, sector other biotechnology & medical research.

• Stock Market
• News Zentek Ltd.

Zentek responds to naysayers and asks “What’s all the fuss about?”

InvestorNews

The dreaded “short report” is an article or research report that focusses on anything and everything negative about a company and tries to make it sound like the most inept or corrupt organization on the planet, typically for the benefit of the author and their acquaintances. Granted in some instances analysis of this type is warranted, but in many cases it’s more of an attempt to make a mountain out of a mole hill and take advantage of “weak” shareholders. By that I mean investors who don’t read each quarterly MD&A, the latest corporate presentation, or Annual Information Form and who could get spooked by what sounds like a legitimate negative case without fully understanding the positive case which led them to invest in the first place. I will give short report authors credit as they typically have done plenty of homework and likely know a lot more about what’s going on in a company than the average long investor, but it isn’t always the fairest representation of a company.

Zentek Ltd. (TSXV: ZEN | OTC: ZENYF) was recently on the receiving end of one of these critical reviews. As a reminder, Zentek (formerly known as ZEN Graphene Solutions Ltd.) is an IP development and commercialization company that uses expertise in nanomaterials and strategic partnerships to break through the barriers of molecular science and uncover new possibilities in healthcare and beyond. The Company is focused on next-gen healthcare solutions in the areas of prevention, detection and treatment.

Daily InvestorNews updates

The report in question was posted on Seeking Alpha early last week and led to a pretty wild day of trading with a 36% price swing from high to low, although the stock ultimately closed higher than the day before the report was published. I’ve read through the Seeking Alpha report and there’s some speculation in there that challenges the imagination a bit. Other parts are simply portraying the glass as half empty, so to speak, versus half full. However, the key issue that caused the frothy trading on March 8 th , in my opinion, is related to a lawsuit filed against Zentek over a year ago that the Company hadn’t disclosed anywhere. They addressed the issue in press releases on March 8 th and further on March 9 th .

Critically, Zentek states “As disclosed March 8, 2022, ZEN received a statement of claim from Graphene Composites Ltd. (“GC”) on January 29, 2021, for breach of confidentiality. The Company maintains that this claim is frivolous based on the fact the information shared by GC was already in the public domain. This position is supported by the public examiner’s response to Graphene Composites patent application #3,097,636 on April 27, 2021, where the examiner rejected 107 out of 108 claims made by Graphene Composites.” To me it’s a bit of a misstep to not get out in front of this from the get go and control the narrative. If they had press released the above quote in April, 2021 (regardless of whether it was thought to be frivolous or immaterial) instead of last week then perhaps all of this uncertainty could have been avoided. Hopefully, the lesson has been learned going forward.

The report of which we are speaking goes on to challenge the production and sales projections of ZenGUARD™ coated masks, especially in light of more recent developments where many major jurisdictions around the world are either reducing or eliminating mask mandates. The author is entitled to their opinion on this but arguably the world has changed somewhat over the last year, and all shareholders can make their own assessment on this topic. To me this is an example of focusing on the glass half empty. Perhaps the Company has over-promised and/or under-delivered with respect to ZenGUARD™ in the past but as I’ve noted, the last year has been the epitome of a moving target. It’s easy to criticize in hindsight.

Regardless of what I think or say, or the opinion of the Seeking Alpha report, as an investor you have to look forward and decide if the stock price today is warranted and if there is upside in the future. Despite the recent disclosure of a year old legal proceeding, the Company has addressed this issue to my satisfaction, so it is a non-issue to me going forward. It raised C$33 M in January and has a quarterly cash burn rate of roughly C$2-C$2.5 M per quarter (and no debt), so they are fine for available working capital. They have several business segments being pursued, of which ZenGUARD™ actually started generating revenue in the final quarter of 2021. Now the onus is on you as an investor to decide if Zentek is worth its C$292 M market cap.

Disclaimer: The author of this Investor.News post, which is published by InvestorNews Inc., may or may not be a shareholder of any of the companies mentioned in this column. No company mentioned has sponsored or paid for this content on Investor.News, and InvestorNews Inc. does not accept opt-in payments from advertisers. While InvestorNews Inc. provides digital media services like video interviews and podcasts to advertisers, not all are paid promotions. Any sponsored video interview will be clearly marked in the summary. The author of this piece is not a licensed investment advisor and makes no recommendations to buy, sell, or hold any securities. If the author holds an investment advisor license, this will be stated in their biography. Conduct your own due diligence by reviewing public documents of any company. For our full legal notices and disclaimers, click here click here .

Editor: InvestorNews

InvestorNews is a capital market & equity funding news source.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Top 10 Trending

Technology metals report (05.24.2024): china’s plan for record cobalt purchases & u.s. defense companies to source critical minerals domestically, cmi summit iii unites global leaders in toronto for landmark two-day critical minerals event on august 21-22, michel pepin on ciscom’s q1 2024 revenue results and board additions.

IN8 Member News

Coeptis therapeutics closes on $4.3 million of series a preferred offering, the critical minerals institute (cmi) unveils first-ever critical minerals list ahead of cmi summit iii, testing to begin of radiology endohedral fullerenes, a milestone in nanotechnology & drug development, diagnos announces closing of second and final tranche of private placement.

InvestorNews Interviews

Jean-francois meilleur on the ongoing demand for uranium and xcite resources’ recent acquisition of the beaver lodge camp, pat bolland with guy bourassa on scandium canada’s recent rights offering, ian fraser discusses fathom nickel’s latest nickel, copper, and cobalt drilling campaign, christopher berlet on tracking the performance of managed gold funds.

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• NVIDIA CORPORATION
• AMD (ADVANCED MICRO DEVICES)
• NIPPON ACTIVE VALUE FUND PLC
• AMAZON.COM, INC.
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Dividend Kings
• Quality stocks
• Trend-Following Stocks
• Momentum stocks
• Dividend Aristocrats
• In Vino Veritas
• Cloud Computing
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Warren Buffett
• Powerful brands
• Let's all cycle!
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

Zentek Ltd. Stock

Ca98942x1024, biotechnology & medical research.

Financials USD CAD

Chart Zentek Ltd.

Latest news about zentek ltd..

Analyst Recommendations on Zentek Ltd.

Press releases Zentek Ltd.

Quotes and Performance

Highs and lows

Managers and Directors - Zentek Ltd.

Delayed Quote Toronto S.E., June 20, 2024 at 03:59 pm EDT

Company Profile

Income statement evolution, quarterly revenue - rate of surprise, sector other biotechnology & medical research.

• Stock Market

• Breakout Boards
• Most Posted
• Most Followed Members
• Active Boards
• My Stocks Activity
• Ticker Buzz Cloud
• Commodities
• Cryptocurrency
• iHub Newswire
• All Company News
• iHub Market News
• News Scanner
• Price & News Alerts
• InvestorsHub Daily
• Newsletters

Market Data

• Live Charts
• Economic Calendar
• Follow Feed
• Trader Alerts
• Price Alerts
• Market Movers
• Options Flow
• Broker Review
• 888-992-3836
• Support Email

Subscriptions

Support: 888-992-3836

Copyright © 2023 InvestorsHub Inc.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Zentek Announces Distribution and Supply Agreement with Henry Schein, Inc. Guelph, ON August 24, 2023 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), a graphene technology development and commercialization company has signed a Distribution and Supply Agreement with Henry Schein, Inc. (Henry Schein). This initial agreement will be for a period of three years and is for Canada and the United States. Sales of ZenGUARD™ surgical masks in the United States will commence upon facility establishment registration and issuance of market clearance from the Food and Drug Administration. Henry Schein is the world’s largest provider of health care solutions to office-based dental and medical practitioners. The Henry Schein team will market and distribute ZenGUARD™ surgical masks to dental practices in the U.S. and Canada. Greg Fenton, CEO of Zentek commented: “Henry Schein has been a leading company in the sales and distribution of health care products for over 90 years and been recognized by FORTUNE® as one of the World’s Most Admired Companies. We are proud to have our ZenGUARD™ surgical masks carried by one of the most respected distributors in the world. We believe this is another meaningful step toward securing volumes in a market segment with stable demand for surgical masks. While our focus is currently on surgical masks in Canada, we look forward to exploring other opportunities for our ZenGUARD™ platform in the dental space with Henry Schein.” About Zentek Ltd. Zentek is an ISO 13485:2016 certified graphene technology company focused on the research, development and commercialization of graphene-based novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. Zentek's patented technology platform ZenGUARD™, is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. Zentek's patent pending ZenARMOR™ technology platform is focused on corrosion protection applications. For further information: [email protected]

$ZTEK - Up 6.4% Pre-Market/ Current Price $1.56 Zentek and McMaster Announce Positive Results for Aptamer-Based Technology with Therapeutic Potential

https://finance.yahoo.com/news/zentek-receives-iso-13485-2016-111500895.html

More news Zentek Files Patent Applications for ZenGUARD™ in Multiple New Jurisdictions Guelph, ON April 5, 2023 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), a graphene technology development and commercialization company, has filed patent applications for ZenGUARD™ in 47 countries. The examiner for the Patent Cooperation Treaty, the international patent law treaty, that reviewed the ZenGUARD™ patent application opined that it met all 3 requirements to be granted a patent: novelty, an inventive step and industrial applicability. The Company has also been granted a patent for ZenGUARD™ by the Canadian Intellectual Property Office, as previously announced on December 7th, 2022. Examiners in other jurisdictions will use these actions as a basis for their own examinations and granting of patents in their respective countries. The patented ZenGUARD™ antimicrobial technology platform has demonstrated it is a powerful solution for deactivating pathogens and increasing bacterial and viral filtration efficiency of both surgical masks and HVAC filters. Based on the above information, the Company has decided to file patents in 47 new jurisdictions, including the United States, Europe, India and others and expects to be successful in all of them. The patent covers the chemical formula for ZenGUARD™, a fabrication method along with its application to various substrates, including surgical mask material, other personal protective equipment (PPE) and heating, ventilation, and air conditioning (HVAC) filters. “We expect our patented ZenGUARD™ antimicrobial platform can provide numerous opportunities to give our business partners a competitive advantage in their respective markets, which we believe will make it a cornerstone for Zentek,” commented Greg Fenton, CEO of Zentek. He continued, “Importantly, this demonstrates our ability to move from a concept in the lab to a patent-protected technology platform that we hope to commercialize in numerous ways with several partners – all with the aim of making their products better, safer, and greener. We expect to follow a similar path for our other nanotechnologies, including ZenARMOR™, our patent-pending corrosion technology, and others.”

Jai-Hinde! Love India & “Grandpa’s Kitchen!!”……” MIX-WELL!!” Team ZENTEK!! Chico

Update Zentek NEWS Zentek Engages Arka BRENStech Pvt Ltd to Develop Opportunities in India Guelph, ON March 30, 2023 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, has signed an agreement (the “Agreement”) with Arka BRENStech Pvt Ltd (“BRENStech”), a company incorporated under the laws of the Republic of India (India), pursuant to which BRENStech will act as a local partner to Zentek as it seeks to develop business opportunities in India. Zentek has been working with Mr. Gaurav Kumar, a director of BRENStech, over the last year to understand the Indian market. BRENStech’s primary focus under the terms of the Agreement will be to establish sales and distribution opportunities for Zentek masks and HVAC filters and potentially other Zentek products as they become available, however BRENStech will also provide services under the Agreement to connect Zentek with university research facilities, assist with the navigation of applicable regulatory regimes, and to source potential manufacturing partners for Zentek’s business opportunities in India and globally. To date, BRENStech has performed market research of the Indian market for surgical masks where samples were trialed in hospitals and clinics and has reported positive feedback and Zentek has shipped 2.1 million masks to support initial sales efforts. The personal protective equipment (“PPE”) market in India is valued at $1 billion USD and India is currently the world’s second largest manufacturer of PPE according to the Economic Times, India. “We see significant opportunities in India, both as a market for Zentek’s innovative products and as a potential manufacturing hub for Zentek going forward” said Greg Fenton, CEO of Zentek. “Having a strong partner in India with business, research and development, regulatory and political connections will be invaluable as we seek to grow our opportunities both in India and globally.” Currently, India is the world’s 5th largest economy and expected to grow to the 3rd largest by 2030 according to the International Monetary Fund. India is projected to host over 1.5 billion people by 2030 making it the highest population in the world. Currently the estimated middle class has approximately 350 million people and targeted to reach 600 million by 2030. India offers significant opportunities for Zentek and its partners: Sales and distribution, strong manufacturing infrastructure along with world-class research and development. About Zentek Ltd. Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. About Arka BRENStech Pvt Ltd. BRENStech is a leading consulting company that is focused on technology and has a history of developing and deploying cutting-edge technologies. The company works primarily in the realm of environmental sustainability and renewable energy but is also well diversified and active in many other areas of industry and is well positioned for companies entering India under joint ventures. BRENStech has been in business for over 10 years and has corporate offices in Gurugram (on the outskirts of New Delhi), Hyderabad, Bangalore, and Chandigarh which provide a presence throughout India. The company also has an extensive network established in the private and public sectors as it works with a wide range of SMEs as well as large multinationals. The company maintains a close working relationship with numerous departments and agencies throughout all levels of Government and participates actively in policy formation. BRENStech offers its partners a strong combination of technical expertise and business knowledge to help bring emerging technologies to market. For further information: Mitch Swergold Tel: (917) 930-8723 Email: [email protected] To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at http://www.sedar.com/ . Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Zentek on Facebook! Zentek on Twitter! Zentek on Instagram! Zentek's Website Zentek on LinkedIn! Copyright © 2023 Zentek Ltd., All rights reserved. You are receiving this email because you opted in via our website. Our mailing address is: Zentek Ltd. 210-1205 Amber Drive Thunder Bay, ON P7B6M4 Canada Add us to your address book Want to change how you receive these emails? You can update your preferences or unsubscribe from this list. Email Marketing Powered by Mailchimp

How about this ? Guelph, ON March 22, 2023 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, announces that SGS Standard Technical Services Co. (“SGS”) recently conducted tests to determine the extent of the antimicrobial properties and the time required to achieve deactivation of bacteria and virus on ZenGUARD™-coated mask material. “Our goal at Zentek from early on in the pandemic was to create a technology that could improve the health and safety of our valued frontline healthcare workers” said Greg Fenton, CEO of Zentek. “Our patented ZenGUARD™ antimicrobial technology with 99.99% bacterial and viral filtration efficiency brings an added level of protection that doctors, nurses and all frontline healthcare providers deserve. We are excited to bring our unique ZenGUARD™ surgical masks to them via our Canadian distribution partnership with Southmedic Inc.” Key Data points Antibacterial testing completed by SGS following AATCC 100-2019 Test Method for Antibacterial Finishes on Textile Material Antiviral testing completed by SGS and followed ISO 18184: 2019 Textiles – Determination of antiviral activity of textile products TCID50 method The ZenGUARD™-coated mask fabric demonstrated over 99.99% antibacterial effectiveness after 1 hour where 260,000 Escherichia Coli (E. coli) Colony Forming Units (CFU) was reduced to under 100 CFU. The untreated control mask samples saw 120,000 E. coli CFU grow to 2.5 million in 1 hour and 1.1 billion in 8 hours The ZenGUARD™-coated mask fabric demonstrated 86.7% antiviral effectiveness after 1 hour against H1N1 and 99.7% after 8 hours These meaningful reductions in bacterial and viral load may have an impact in the reduction of infectious disease in high-risk environments Impact in High-Risk Environments In the context of high-risk indoor settings, such as hospitals where doctors, nurses and other healthcare professionals and patients wear surgical masks and are exposed to dangerous bacteria and viruses daily, this data offers compelling evidence that ZenGUARD™-coated mask material can provide additional protection with the strong antimicrobial properties of ZenGUARD™. The reduction in bacterial and viral growth in the mask materials may contribute to protecting doctors, nurses, other hospital staff and patients, as well as long term care residents and their caretakers, from mask acne to potentially preventing significant disease from bacterial or viral infections. Southmedic Inc. is Zentek's exclusive distribution partner in Canada for hospitals, clinics, long-term care, nursing homes and community health care services. For any purchase requirements, please contact Southmedic Customer Service at [email protected] or by phone at 1-800-463-7146, Mon - Fri 8:30am - 5:00pm. About Zentek Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. For further information: Mitch Swergold Tel: (917) 930-8723 Email: [email protected] To find out more about

Maybe this will help https://finance.yahoo.com/news/zentek-announces-successful-phase-2-130000568.html

C'mon ZEN! Still under 3$... Need to sign a nice "DEAL$$$$" & this will grow wings! I've been holding underwater.... here.... Knowing ZEN has the Goods. It's time to get back over 5$/share on volume Mr. Fenton! Chico

Update https://finance.yahoo.com/news/zenteks-zenguard-tm-patent-application-130000917.html

New update https://finance.yahoo.com/news/zentek-provides-battery-technology-development-120000124.html

Zentek’s ZenGUARD™ Patent Application Allowed by the Canadian Patent Office Guelph, ON September 27, 2022 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property (IP) development and commercialization company, is pleased to announce that on September 16, 2022, it’s Canadian patent application directed to its ZenGUARD™ technology, for use on personal protective equipment (“PPE”), and heating, ventilation, and air conditioning (“HVAC”), has been allowed by the Canadian Intellectual Property Office including all 54 claims made in the application. Zentek is now working with its IP counsel to map out the strategy to extend patent protection of its commercial rights in all global jurisdictions of interest. “This is tremendous news for our company and shareholders,” said Greg Fenton, CEO for Zentek. “Our team has worked diligently with our patent attorneys to map out a strong strategy to protect ZenGUARD™ and our other graphene-based technologies. By moving this technology from the lab all the way through to a patent and commercialization, this milestone validates the Zentek business model of being an intellectual property development and commercialization company. In two short years we have taken this game changing technology for the fight against Covid-19 and other airborne pathogens from a concept to a fully protected asset of the company.”

September 20, 2022 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, announces that Greg Fenton, CEO, will hold investor meetings and present at this year’s Sidoti Small-Cap Virtual Investor Conference, which will be held September 21-22, 2022. Mr. Fenton will deliver his corporate presentation on Thursday, September 22nd at 12:15PM ET, and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_JpxPXpukRwSFbGSx-di-BA The Sidoti Small Cap Conference is a virtual event featuring dynamic, small-cap companies interacting with top institutional investors. Sidoti is a provider of independent securities research focused on small and micro-cap companies and the institutions that invest their securities. Their investor conferences have emerged as a leading forum for interaction between issuers and investors in the small and micro-cap investment community. “The value proposition for Zentek is tremendous as our company continues to advance its IP pipeline and commercialization opportunities in a number of areas, most notably with ZenGUARD™ in the personal protective equipment and indoor air filtration markets,” said Greg Fenton, CEO. “We’re in good company at this year’s conference and look forward to reinforcing our unique value proposition with US investors.” For more information, and to register, visit https://www.sidoti.com/events/fall-small-cap-virtual-conference . About Zentek Ltd. Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. For further information: Tyler Dunn Tel: (306)717-6745 Email: [email protected]

Zentek Provides Update on Icephobic Coating Technology Guelph, ON September 19, 2022, Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual property development and commercialization company, has successfully completed sand erosion testing at the National Research Council (“NRC”) in Ottawa and rain erosion testing at the Anti-icing Materials International Laboratory (“AMIL”) in Quebec on Zentek’s patent-pending Icephobic Coatings. These results, when taken with the strong performance under accelerated ageing announced March 14, 2022, demonstrate that the company’s icephobic technology is durable in adverse conditions for both wind turbine and drone industries, where Zentek is currently maintaining its focus. Summary of overall results to date as reported by the NRC and AMIL: As reported in November 2021, icephobicity tests at the NRC yielded strong and consistent results with an average shear stress of 20 kPa required to passively remove ice accretion (results under 100 kPa are considered to demonstrate low adhesion). Retesting a year later yielded the same results, demonstrating strong stability. Flight tests in real-world icing conditions demonstrated good performance of Zentek’s coating, with results indicating retardation of ice accretion (icephobicity) and low adhesion to accreted ice. 1,000 hours of UV exposure, equivalent to two years of UV damage in Canada, slightly increased the ice adhesion properties to 43 kPa, which is still considered to be an effective coating in removing ice. Sand erosion testing demonstrated medium to good performance at a high speed of 540 km/h. Rain erosion testing at AMIL demonstrated good performance at 160 km/h and 320 km/h based on our interpretation, speeds at which the leading edge of wind turbines blade tips are exposed. NRC drone testing demonstrated consistent results of maintaining control of rotor thrust in icing conditions while uncoated blades failed to maintain thrust in the same indoor controlled environment. NRC is preparing for outdoor, real-world environment testing of drone rotor blades with Zentek’s icephobic coating this winter. AMIL is testing the performance of Zentek’s coating on a small wind turbine in an indoor controlled environment. “We are very happy with both the performance and durability test results for our icephobic coating and look forward to continued testing and demonstration of our technology,” said Greg Fenton, CEO of Zentek. “Ice accretion is a significant problem in the drone and wind turbine industries with few robust solutions currently available. We believe our patent-pending technology may be a new innovative approach to addressing a significant global need and look forward to continued discussions with drone and wind turbine market participants who see value in potentially more effective icephobic technologies.” Zentek has filed a full patent application with the Patent Cooperation Treaty, the international patent office, on August 2nd, 2022, for Nanomaterial-Enhanced Elastomer for Passive Ice Accretion Prevention. The patent application will publish approximately 6 months from the date of filing, marking the beginning of the 12-month national phase for Zentek to apply directly in each country of interest. About Zentek Ltd. Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. For further information: Tyler Dunn Tel: (306) 717-6745 Email: [email protected] To find out more about Zentek Ltd., please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN’s SEDAR profile at http://www.sedar.com/ . Forward-Looking Statements This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

September 15, 2022 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V:ZEN an intellectual property development and commercialization company, reports, further to its press release dated April 11, 2022, that it has received the final report from Phase 1 testing under its Innovation Solutions Canada (“ISC”) Testing Stream contract, which notes that all Phase 1 targets were met including: (i) a sufficient reduction in live airborne test organisms without modification to existing HVAC systems, (ii) no reduction in air flow rates, and (iii) no significant shedding of the ZenGUARD™ coating. ZenGUARD™-coated HVAC filters demonstrated a maximum improvement of 99% compared to equivalent MERV-rated uncoated filters using a bacteriophage (a SARS-COV-2 surrogate). “The significant increase in filtration efficiency of pathogen-laden water droplets, without an impact to airflow rates, creates a potentially powerful solution in the HVAC space,” said Greg Fenton, CEO of Zentek. “Working with current systems, and not requiring additional energy or changes to existing equipment, our technology could be a simple and energy-efficient approach to providing cleaner air for indoor spaces and is highly supportive of current global indoor air quality initiatives.” Phase 1 testing was conducted by CremCo Laboratories with assistance by the Aerospace Research Centre, a department of the National Research Council of Canada. Zentek is now in Phase 2 Testing at the National Research Council to demonstrate a reduction in live airborne surrogate contamination within a modular classroom environment, simulating a real-world environment. The Company will report results when completed and validated. About Zentek Ltd. Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario. For further information: Tyler Dunn? Tel: (306) 717-6745? Email: [email protected]

wow 14.99 this morn>??? what~! Float 99,118,058 03/01/2022

Zentek Receives Approval for Nasdaq Listing - https://t.co/8d3knQ5Fce — Zentek Ltd. (@zentekltd) March 7, 2022

Zentek Ltd., formerly ZEN Graphene Solutions Ltd., is a Canada-based intellectual property development and commercialization company. The Company is focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. The Company's technology helps filter and deactivate pathogens to reduce the risk of transmission. The Company is focused on commercializing ZenGUARD, which is a hydrophilic, water attracting coating that adsorbs bacteria and virus-laden aerosols and deactivates them, increasing public safety, and reducing the risk of transmission of COVID and other pathogens. The Company is developing a graphene-based fuel additive that can reduce greenhouse gas (GHG) emissions from diesel and bio-diesel fuels. It also intends to focus on commercializing few layers graphene and developing technology to produce monolayer graphene. The Company's manufacturing facility is located at 1123 York Rd, Guelph, Ontario .

ZENYF changed to ZTEK. Moved to the Nasdaq from the OTC: https://otce.finra.org/otce/dailyList?viewType=Deletions https://www.sec.gov/Archives/edgar/data/1904501/000106299322008179/exhibit99-1.htm

So, what’s “graduation day” going to bring ? Something good I hope !

I hate this short shit…. March 8, 2022 Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization company focused on next-gen healthcare solutions has become aware of certain rumours and allegations being circulated, and categorically refutes the egregious allegation regarding the theft of intellectual property from Graphene Composites Ltd. On January 29, 2021, the Company was served with a statement claim issued by Graphene Composites Ltd. and is in the process of defending the action, which it considers frivolous and without merit. The Company has considered the allegations as set out in the claim and, in light of the facts, the lack of clarity in the claim, and, based on discussions with the Company’s litigation counsel, the assessment of the merits of the claim and the defenses available to the Company, and the Company’s conclusion is that the risk of the Company suffering loss in respect of the claim is remote, and therefore the Company determined the claim not to be material or constituting ”significant litigation” pursuant to the policies of the TSX Venture Exchange. The Company continues to view this claim as frivolous and will continue to vigorously defend itself against these allegations. The Company is aware of a 2,904,839 share Consolidated Short Position (less than 3% of total shares outstanding) in the marketplace as of March 1, 2022. Furthermore, the Company believes these false allegations were meant to hurt the Company’s credibility.

Short report on Zentek Says previous partner claims Zentek stole its technology. also claims masks won't sell.

ZENTK, movin uptown !!!

Zen guard masks online ! https://vitalhealthsupplies.ca/

Very encouraging presentation this morning, pissed that I missed the first 1/2. Hope they post it.

Indeed Tunert! ZEN is just getting started. Glad I have some shares; their IP is killer. GRAPHENE - They are just touching the surface of this revolutionary product. Worth doing the D.D. on ZEN if you haven't. Some folks might want to own a few shares after they do so? All IMHO Chico

"Revenue stream of 100 mill? Try Gross Margin of 240 mill. That's already set up with the contracts to buy enough GO for 3 billion mask equivalents over 6 months. Do the math @ 4 cts a mask. (Zen gives a range of 3-6 cts a mask) The contract is a 6 billion annual run rate. 6 bill times 4 cts...... 240 mill Gross margin (not Rev, Gross margin) If we assume a 50% margin, Rev would be about 480 mill.... Market cap is therefore approx 1 times sales of masks/mask equiv line. Nothing yet said of the spit test contribution, which was said to be out 1st qtr. (another Line) Treatment silver/GO Line prob will take a year or more, but de-icer stuff, maybe a year. Then there is the Biggie.... fuel additive... 2-4 years??

Thanks much for the DD Chico! As you said, it depends on how well the stock is received and perceived. Also to what degree they have commercial success with the products and technology described below. It certainly sounds exciting and promising. Murocman

Please see the following D.D. -Murocman (The following from Johan/Yahoo board) "A complete 180 pivot to R&D which turned very successful due to universities across Canada accruing interest in the Graphene derived from the Albany graphite. The resulting partnerships has allowed Zentek the opportunity to commercialize many IP developed in collaboration with their own researchers and experts across the country. Now finalizing commercialization of the Anti-microbial compound which initialized a growing cult interest in the company. Those willing to put in the research do not have a hard time finding reasons to invest in what is turning into a burgeoning IP-spinoff company with primary focus on Healthcare. Current commercial capacity suggests a procurement of around what is equivalent to material used to coat 9.6 billion masks, with ability to spread that production capacity into applications as they are approved, among which include: Masks 1% of global >$200 mil/year, MASKS ALONE! Gloves 1% of global >$50mil/year, HVAC filters 1% of global >$150mil/year, Medical Gowns, caps, booties, Bedsheets, High-touch surfaces, Cardboard, paper, & other packaging material, Bandages.. Much more Compound also undergoing human trials next year for pharmaceuticals. Expected testing multiple skin conditions and gut infections. Early safety tests suggests this will be very safe with very high potency. Further, the company expects to release a highly competitive rapid aptamer test for localized usage and results under 10 minutes. To be developed for everything from STD's to cancer. New aptamers are expected to require an additional one to two months to be integrated within the pathogen detection system Will seek to develop: (i) commercially synthesized aptamers for the detection of COVID-19; (ii) aptamer deposition on screen printed electrodes; (iii) an automated detector device that adds the fluidic buffers to the sensor and integrates a potentiostat which measures impedance indicating the presence of absence of the targeted pathogen; and (iv) software that connects the detector to a device and management system. A prototype of the system is expected to be completed in 2022, at which point a final commercialization strategy will be determined based on the market data. The Corporation then intends to request approval for the rapid test under the interim order provision at Health Canada. As an IP development company, they are involved in many special projects: • Ice-phobic coating, planes, pavement, power lines • Anti-corrosive coating, heavy maritime potential • Fuel additives, aerospace fuels, diesels and gasoline • Concretes, small 0.02% graphene improves tensile and compressive strengths by >40-80% • Batteries (mentioned recently by CEO but not much has been disclosed ) • 3D conductive filaments for a variety of applications, • Graphene quantum dot synthesis and applications, • Graphene synthesis, has secured patent rights for in-house production through Guelph University • Upscaling recycled plastics, • Magnetic filament fabrication, According to information circular, any of these could justify another pilot plant scale application 2022. As a results of being a graphite play, Zentek Ltd. retains ownership of the Albany deposit, of which is not priority but could be outsourced or sold to further pursue the intense future proofing that the IP could provide." IMHO & Speculation this will be a $10 NASDAQ stock in 2022. Do your own D.D. & form your own conclusions Chico

Market cap is already almost $500M. Might limit upside unless they start producing a large revenue stream ($100M +) GLTA, Murocman

ZENTECH listing to NASDAQ soon! Worth your Due Diligence folks! IMHO- their I.P. & patents will bring in 100's of millions to this company & this is going multiples higher. Graphene Medical & industrial I.P. with a Graphite Mine "undeveloped kicker"! The market does not yet recognize what this company has but it won't be long!!! All IMHO & all Chico

https://www.siliconinvestor.com/subject.aspx?subjectid=59578 And another SI Zen board https://www.siliconinvestor.com/subject.aspx?subjectid=59202 https://stockhouse.com/companies/bullboard?symbol=v.zen https://ceo.ca/zen And finally https://www.reddit.com/r/zengraphene/

Zentek! $$$ Graphene to the next level! eom Chico =)

Hi there - Could you link us to those boards ?

Effective Nov. 1,2021 Zen Graphene Solutions Ltd. will change to Zentek Ltd. https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Hi guys and gals.... been a while. this board has been crickets for so long, I migrated to the SI board. Since things are picking up, I thought I'd stick my head in. IMO, the next 5 or 6 months are going to be EPIC. If looking for more Info, check out SI, CEO, or Reddit. Reddit seems to be better for navigating and finding real intel. SI's 2 zen boards are better for conversations. Back later.

Certainly can’t complain about the direction and pace of the PPS. IM LOVING IT. (Of course now ,hindsight, I wish I had picked up more initially)

https://finance.yahoo.com/news/zen-graphene-solutions-trebor-rx-144500352.html

Zentek Ltd (ZTEK)

Detailed Quote

Ztek latest news.

• Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] 05/28/2024 09:46:21 AM

Add ZTEK Alert

Zentek Ltd.

NasdaqCM:ZTEK Stock Report

Market Cap: US$110.5m

Zentek Management

Management criteria checks 2/4.

Zentek's CEO is Greg Fenton, appointed in Dec 2020, has a tenure of 3.5 years. total yearly compensation is CA$325.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.86% of the company’s shares, worth $3.16M. The average tenure of the management team and the board of directors is 1.5 years and 2.7 years respectively.

Key information

Greg Fenton

Chief executive officer

Total compensation

Recent management updates

Zentek ltd. announces board and management changes, zentek ltd. announces board changes, zentek ltd. elects john snisarenko as director, zentek ltd., annual general meeting, oct 05, 2023, zentek ltd. announces updates to senior management team, zentek ltd. appoints lisa sim to the board of directors, recent updates, zentek ltd. provides zenguard business update, zentek ltd.'s subsidiary triera biosciences ltd. completes testing of its c19hba aptamer as potential therapeutic, zentek ltd. completes study quantifying energy and emission savings of zenguard(tm)-enhanced hvac filters, new minor risk - share price stability, zentek ltd. reports successful testing of aptamer against omicron covid-19 variant, zentek ltd. announced a financing transaction, zentek ltd. completes return on investment analysis for canadian healthcare system, zentek ltd announces the successful results of a recent study conducted by particleone, zentek ltd. announces the results of study comparing the viral filtration efficiency of its zenguard-enhanced merv 9 filters with an uncoated merv 9 filter, first quarter 2024 earnings released: ca$0.03 loss per share (vs ca$0.051 loss in 1q 2023), zentek and mcmaster announce positive results for aptamer-based technology with therapeutic potential, zentek receives a deficiency letter from nasdaq stock market llc, full year 2023 earnings released: ca$0.14 loss per share (vs ca$0.13 loss in fy 2022), albany graphite corp. acquired albany graphite project from zentek ltd. for approximately cad 136 million., zentek ltd. introduces a novel corrosion protection technology: zenarmor, zentek ltd. receives the final report for phase 2 testing of zenguardtm for use in heating, zentek ltd. announces appointment of mitch swergold as director of investor relations, zentek ltd announces successful phase 2 results of hvac testing, less than half of directors are independent, zentek ltd. provides update on battery technology development, zentek provides update on icephobic coating technology, zentek ltd. provides update on hvac testing, zentek enters manufacturing and supply agreement with viva healthcare packaging, zentek ltd., annual general meeting, sep 29, 2022, zentek files provisional patent on the use of zenguard as an anti-inflammatory agent, zentek ltd. appoints ilse treurnicht to its board of directors, zentek ltd. provides update on zenguardtm patent status, zentek ltd. announces chief financial officer changes, zentek ltd. announces start of phase two testing of zenguardtm -coated filters, zentek ltd. announces filing of provisional patent for fire-retardant additive, zentek ltd. appoints ravi kaza to its advisory board, zentek ltd. announces development of graphene-wrapped silicon anodes, zentek ltd. announced that it has received cad 10.009022 million in funding, zentek ltd. announced that it expects to receive cad 10.009022 million in funding, zen graphene solutions and trebor rx announce health canada approval for zenguardtm mask, zen graphene solutions ltd. develops stable diesel fuel additive, zen graphene solutions ltd. announced that it has received cad 4.337998 million in funding, zen graphene solutions ltd. announced that it expects to receive cad 2 million in funding, zen graphene solutions ltd. announces successful testing of its graphene compound against antimicrobial-resistant bacteria, zen graphene solutions and trebor rx corp. announce successful health canada testing requirements of surgical masks, zen graphene solutions announces initial phase 2 cytotoxicity results for its graphene-based compound, zen graphene solutions ltd. announces management changes, zen graphene solutions ltd. provides update on cytotoxicity testing of graphene-based compound and effectiveness of graphene-based coating, zen graphene solutions ltd. appoints gregory fenton as new chief executive officer, zen graphene solutions ltd. announces new research collaboration agreement on carbon aerogels with deutsches zentrum fuer luft- und raumfahrt e. v, zen graphene solutions ltd. solutions signs 2 year extension with chemisar laboratories inc, zen graphene solutions and guelph university researchers file patent on graphene oxide production method, zen graphene solutions ltd. develops novel graphene-based virucidal ink with 99% effectiveness against covid-19, zen graphene solutions ltd. announced that it has received cad 2.05 million in funding, ceo compensation analysis.

Compensation vs Market : Greg's total compensation ($USD237.52K) is below average for companies of similar size in the US market ($USD683.56K).

Compensation vs Earnings : Greg's compensation has been consistent with company performance over the past year.

Compensation

Mr. Gregory Fenton, CFA, also known as Greg, has been Chief Executive Officer of Zentek Ltd. (formerly known as ZEN Graphene Solutions Ltd.) since December 8, 2020 and served as its Chief Strategy Officer ... Show more

Leadership Team

Average Tenure

Experienced Management : ZTEK's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Average Age

Experienced Board : ZTEK's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Credit Card Offers
• Best Free Checking
• Student Loans
• Personal Loans
• Car Insurance
• Mortgage Refinancing
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Zentek announces board and management changes.

GUELPH, ON / ACCESSWIRE / May 3, 2024 / Zentek Ltd. (" Zentek " or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, announces the following changes to its board and management teams: (i) Dr. Francis Dubé has resigned as Chief Operating Officer of the Company effective May 1, 2024, and (ii) Brian Bosse has resigned as a director of the Company effective May 3, 2024, and has been appointed to the Company's advisory board.

"Six years ago, we as shareholders of Zenyatta Ventures worked together to replace the board of directors and undertook a mission to create a better company. I had the privilege and honour to be the first CEO and Chairman of our Company and I am incredibly grateful and want to say a huge thank you to all shareholders for the trust, friendships, and collaborations that we have shared over the last six years." said Francis Dubé. "My retirement is part of a process that started last fall when I began transitioning from the company and returned to my optometry practice to resume serving my local community as an optometrist. I will continue to help in a smaller role, but the Company has built an incredible team under Greg's strong leadership. I firmly believe in the foundation we have collectively established, and I am thrilled and excited to witness the growth and commercialization of our technologies, including ZenGUARD™ and our aptamer platform."

"On behalf of all shareholders, I would like to thank Francis for his invaluable contribution to Zentek over the past six years. He was the catalyst that led the movement to create the change for what we have become today. I look forward to his continuing contributions to the company and I wish him all best in his future endeavors." commented CEO, Greg Fenton.

"On behalf of the Zentek board of directors, I would like to thank Brian for his service to the board of directors and shareholders in general. We look forward to his continuing contribution as part of the Zentek advisory board." commented Eric Wallman, Chairman of Zentek board of directors.

In line with Mr. Bosse's appointment to the Company's advisory committee, the Company has granted to Mr. Bosse stock options to purchase 40,000 common shares of the Company at a price of $1.42 per common share, which shall vest on May 3, 2025, and expire on May 3, 2027.

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek has a global exclusive license to the Aptamer-based platform technology developed by McMaster University which is being jointly developed Zentek and McMaster for both the diagnostic and therapeutic markets.

For further information:

Ryan Shacklock Senior VP, Strategy & Business Development Email: [email protected] Phone: 306-270-9610

To find out more about Zentek, please visit our website at www.Zentek.com . A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/ .

Forward-Looking Statements

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Zentek Ltd.

View the original press release on accesswire.com

Zentek Ltd. (ZTEK)

Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops graphene oxide synthesis and graphene synthesis. The company was formerly know... [Read more]

Financial Performance

In 2022, Zentek's revenue was 72,855, a decrease of -79.02% compared to the previous year's 347,183. Losses were -14.41 million, -54.52% less than in 2021.

• Press Press Releases
• Conversation

Zentek Completes Case Study on HVAC Total Cost of Ownership Savings for the City of Toronto

GUELPH, ON / ACCESSWIRE / May 7, 2024 / Zentek Ltd. (" Zentek " or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company is pleased to announce t...

Zentek and Triera Biosciences Ltd. Achieve Positive Results Against Avian Influenza (H5N1) using Multivalent Aptamer Technology

GUELPH, ON / ACCESSWIRE / May 6, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd.

Zentek Announces Board and Management Changes

GUELPH, ON / ACCESSWIRE / May 3, 2024 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, announces the following cha...

Zentek Provides ZenGUARD(TM) Business Update

GUELPH, ON / ACCESSWIRE / April 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased to...

Zentek Announces U.S. Distribution Agreement for ZenGUARDTM-Enhanced Surgical Masks with Medwell Solutions

GUELPH, ON / ACCESSWIRE / April 3, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announce t...

Zentek Announces Promising Preclinical Safety and Toxicity Results achieved by Triera Biosciences Ltd. for C19HBA

GUELPH, ON / ACCESSWIRE / March 25, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), announces that its wholly-owned subsidiary Triera Biosciences Ltd.

Zentek Announces Positive Therapeutic Results achieved by Triera Biosciences for C19HBA

GUELPH, ON / ACCESSWIRE / January 30, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN) announces that its wholly-owned subsidiary Triera Biosciences Ltd.

Zentek Completes Study Quantifying Energy and Emission Savings of ZenGUARD(TM)-Enhanced HVAC Filters

GUELPH, ON / ACCESSWIRE / January 22, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, is pleased to announc...

Zentek Announces Eric Wallman Appointed as Chairman of the Board

GUELPH, ON / ACCESSWIRE / January 19, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, announces that effect...

Zentek Launches Triera Biosciences Ltd.

GUELPH, ON / ACCESSWIRE / December 13, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company announces ...

Zentek and 1Click Heating and Cooling Sign Distribution Agreement

GUELPH, ON / ACCESSWIRE / December 8, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company and 1Click Heating and...

Zentek Announces Grant of Stock Options

GUELPH, ON / ACCESSWIRE / November 30, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK);(TSXV:ZEN), an intellectual property technology development and commercialization company announces ...

Zentek Reports Successful Testing of Aptamer Against Omicron Covid-19 Variant

GUELPH, ON / ACCESSWIRE / November 29, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company announces ...

Zentek Announces Update on the Albany Graphite Project

GUELPH, ON / ACCESSWIRE / November 21, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company provides an update on...

Zentek Reports Improvements and Expansion of its Aptamer-Based Platform Technology

GUELPH, ON / ACCESSWIRE / November 15, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company announces ...

Zentek Completes Return on Investment Analysis for Canadian Healthcare System

GUELPH, ON / ACCESSWIRE / October 17, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN), a graphene technology development and commercialization company is pleased to announce com...

Zentek Announces Voting Results of Annual and Special Meeting

Guelph, Ontario--(Newsfile Corp. - October 10, 2023) - Zentek Ltd.  (Nasdaq: ZTEK) (TSXV: ZEN) ("Zentek" or the "Company"), an intellectual property development and commercialization company, announce...

Zentek Announces Successful Aptamer Testing for Longevity of Protection and Minimum Effective Dose

GUELPH, ON / ACCESSWIRE / October 10, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is pleased ...

Zentek Announces the Launch of Subsidiary for Aptamer-Based Platform Technology

GUELPH, ON / ACCESSWIRE / October 5, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company announces the...

Zentek Provides Corporate Update

GUELPH, ON / ACCESSWIRE / October 4, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), a graphene technology development and commercialization company is pleased to provide a cor...

Zentek to Showcase ZenGUARD(TM) for HVAC at BUILDEX Alberta 2023

GUELPH, ON / ACCESSWIRE / September 25, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company is pleased to announ...

Zentek Announces Annual General Meeting on Thursday October 5th, 2023, at the Delta Hotel in Guelph, Ontario

GUELPH, ON / ACCESSWIRE / September 21, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is please...

Zentek's ZenGUARD(TM)-Enhanced Filters Demonstrate Robust Return on Investment in ParticleOne Study

GUELPH, ON / ACCESSWIRE / September 11, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), an intellectual property technology development and commercialization company is please...

Zentek Announces Breakthrough Results in Viral Filtration Efficiency with Dust Loading

GUELPH, ON / ACCESSWIRE / September 6, 2023 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company is pleased ...

Zentek Announces Distribution and Supply Agreement with Henry Schein, Inc.

GUELPH, ON / ACCESSWIRE / August 24, 2023 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSX-V:ZEN), a graphene technology development and commercialization company has signed a Distribution ...